Last reviewed · How we verify
Amphotericin B Lipid emulsion
Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause cell death.
Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause cell death. Used for Systemic fungal infections (invasive aspergillosis, candidiasis, cryptococcosis), Amphotericin B-susceptible fungal infections in immunocompromised patients.
At a glance
| Generic name | Amphotericin B Lipid emulsion |
|---|---|
| Also known as | Amphomul |
| Sponsor | Bharat Serums and Vaccines Limited |
| Drug class | Polyene antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amphotericin B is a polyene antifungal that selectively targets ergosterol, a sterol unique to fungal cell membranes. By binding to ergosterol, it forms ion channels that increase membrane permeability, leading to leakage of cellular contents and fungal cell death. The lipid emulsion formulation reduces nephrotoxicity by altering the drug's distribution and reducing binding to human cell membranes.
Approved indications
- Systemic fungal infections (invasive aspergillosis, candidiasis, cryptococcosis)
- Amphotericin B-susceptible fungal infections in immunocompromised patients
Common side effects
- Nephrotoxicity (elevated creatinine, reduced GFR)
- Infusion-related reactions (fever, chills, rigors)
- Hypokalemia
- Anemia
- Hypomagnesemia
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amphotericin B Lipid emulsion CI brief — competitive landscape report
- Amphotericin B Lipid emulsion updates RSS · CI watch RSS
- Bharat Serums and Vaccines Limited portfolio CI